This research area aims at creating capabilities for discovery and validation of diagnostic, predictive, prognostic and therapeutic biomarkers. In addition, building capabilities for systems immunology and systems virologi of COVID-19 infected patients, as well as concepts towards individualized monitoring and targeting of cytokine storms are also part of the aim.
This area consists of 6 individual projects, funded a total of 6,6 MSEK. Led by researchers at KTH Royal Institute of Technology, Karolinska Institutet, University of Gothenburg, Lund University and Linköping University.
Coordinator: David Gotthold, KTH Royal Institute of Technology
Scientific lead: Jacob Odeberg, KTH Royal Institute of Technology, and Petter Brodin, Karolinska Institutet
Identification of plasma biomarkers for risk stratification of hospitalised Covid-19 patients
Jacob Odeberg, KTH
Prediction of severe disease in Covid-19
Lars-Magnus Andersson, University of Gothenburg
Taking back the control of the SARS-CoV2 antiviral immune response as a mean to neutralize the COVID19 disease pathogenicity
Marie Larsson, Linköping University
Systems immunology analyses of the cytokine storm in COVID-19
Petter Brodin, Karolinska Institutet
Establishing a biobank of clinical specimens for studying evolution of viral diversity and development of immune response, including inflammation, seroprevalence and protective antibodies, in SARS-Cov2 infection (Research project)
Patrik Medstrand, Lund University
Dynamics and longevity of the specific adaptive immune response in COVID-19 patients
Davide Angeletti, University of Gothenburg